Citius Oncology, Inc.
CTOR
$0.94
$0.011.17%
NASDAQ
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 140.86% | 126.97% | 8.34% | 9.31% | 33.00% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 114.20% | 95.25% | 17.60% | 14.34% | 34.48% |
| Operating Income | -86.32% | -72.95% | 0.02% | -14.34% | -34.48% |
| Income Before Tax | -78.91% | -66.70% | -0.87% | -15.22% | -35.33% |
| Income Tax Expenses | -79.72% | -31.23% | 51.80% | 83.47% | 62.60% |
| Earnings from Continuing Operations | -73.32% | -63.62% | -2.41% | -17.08% | -36.13% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -73.32% | -63.62% | -2.41% | -17.08% | -36.13% |
| EBIT | -86.32% | -72.95% | 0.02% | -14.34% | -34.48% |
| EBITDA | -- | -- | -- | -- | -- |
| EPS Basic | -27.23% | -26.62% | 6.90% | -9.65% | -29.29% |
| Normalized Basic EPS | -30.94% | -28.49% | 8.27% | -7.96% | -28.62% |
| EPS Diluted | -27.23% | -26.62% | 6.90% | -9.65% | -29.29% |
| Normalized Diluted EPS | -30.94% | -28.49% | 8.27% | -7.96% | -28.62% |
| Average Basic Shares Outstanding | 31.45% | 20.38% | 11.84% | 7.66% | 5.32% |
| Average Diluted Shares Outstanding | 31.45% | 20.38% | 11.84% | 7.66% | 5.32% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |